SuperworthBausch Health Companies profit margin BHC
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- −10.1%
- Operating margin, 12 months
- 8.1%
- Net margin on a year earlier
- −11.1 pts
- Peer median
- 11.1%
Over the twelve months to Jun 30, 2026, Bausch Health Companies kept −10.1% of its revenue as net profit, with an operating margin of 8.1% and a gross margin of 71.8%.
Five years earlier its net margin was −15.2%.
The median for 10 large drugmakers of a similar size is 11.1%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 1.5% | 17.7% | 70.7% |
| FY2024 | −0.5% | 16.1% | 71.1% |
| FY2023 | −6.8% | 11.0% | 70.8% |
| FY2022 | −2.8% | 5.6% | 70.9% |
| FY2021 | −11.2% | 5.3% | 71.6% |
| FY2020 | −7.0% | 8.4% | 72.0% |
| FY2019 | −20.8% | −2.4% | 72.7% |
| FY2018 | −49.5% | −28.4% | 71.9% |
| FY2017 | 27.6% | 1.2% | 71.1% |
| FY2016 | −24.9% | −5.9% | 73.4% |
| FY2015 | −2.8% | 14.6% | 75.8% |
| FY2014 | 11.1% | 24.4% | 73.5% |
| FY2013 | −15.0% | −7.1% | 68.0% |
| FY2012 | −3.3% | 2.2% | 72.6% |
| FY2011 | 6.5% | 12.2% | 72.2% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −10.1% | −11.1 pts | 8.1% | |
| Q1 FY26 | −11.5% | −11.1 pts | 5.6% | |
| Q4 FY25 | 1.5% | +2.0 pts | 17.7% | |
| Q3 FY25 | 3.6% | +5.5 pts | 18.9% | |
| Q2 FY25 | 1.0% | +6.1 pts | 16.2% | |
| Q1 FY25 | −0.4% | +4.7 pts | 15.8% | |
| Q4 FY24 | −0.5% | +6.3 pts | 16.1% | |
| Q3 FY24 | −1.9% | +9.4 pts | 14.2% | |
| Q2 FY24 | −5.1% | −2.9 pts | 11.4% | |
| Q1 FY24 | −5.1% | −0.7 pts | 11.9% | |
| Q4 FY23 | −6.8% | −4.0 pts | 11.0% | |
| Q3 FY23 | −11.3% | −14.4 pts | 4.3% |
Against its peers
Companies in Drug Manufacturers - General nearest Bausch Health Companies' size, closest first, today.
| Company | Profit margin |
|---|---|
| BHCBausch Health Companies | −10.1% |
| PBHPrestige Consumer Healthcare | 15.6% |
| HRMYHarmony Biosciences | 18.9% |
| NRIXNurix Therapeutics | 42.0% |
| ANIPANI Pharmaceuticals | 11.1% |
| OGNOrganon | 3.4% |
| PAHCPhibro Animal Health | 6.6% |
| LQDALiquidia | 30.7% |
| ARQTArcutis Biotherapeutics | 6.1% |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 2.0% |
| Peer median | 11.1% |
Where Bausch Health Companies ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Bausch Health Companies
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.